BeiGene Ltd ADR
BGNE: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$444.75 | Nvxmkq | — |
BeiGene: Initiating Coverage With a No-Moat Rating; Shares Fairly Valued
We initiate coverage of BeiGene with a fair value estimate of HKD 125 per share and a no-moat rating. Focusing on oncology therapeutics, BeiGene is a commercial-stage biotechnology company with global revenue. We think the shares are fairly valued and investors should wait for a better entry point. The key upside to our valuation depends on patent-protected portfolio expansion rather than indication expansion from existing commercialized drugs.